Optimism amid grim forecast: Dr. Isaac Y. Kim disputes projections of rising prostate cancer deaths, predicting declines through better diagnostics and treatments. Screening evolution: PSA testing, ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about navigating treatment option in prostate cancer. Advancements in prostate ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on ...

Extracellular vesicles shed by prostate cancer cells to the bloodstream contain tumor-derived material that can be used as biomarkers of therapy response and resistance in patients with metastatic ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...

orgovyx (relugolix) is a medicine used to treat advanced prostate cancer in adults. Advanced prostate cancer means that the cancer has spread outside of the prostate. Advanced cancers have often come ...

Prostate cancer, an uncontrolled growth of cells in the prostate, a gland in the male reproductive system located below the bladder, is one of the most common cancers that affects men, especially in ...